Literature DB >> 22879062

Adenosine signaling in glioma cells.

Stefania Ceruti1, Maria P Abbracchio.   

Abstract

Purines and pyrimidines are fundamental signaling molecules in controlling the survival and proliferation of astrocytes, as well as in mediating cell-to-cell communication between glial cells and neurons in the healthy brain. The malignant transformation of astrocytes towards progressively more aggressive brain tumors (from astrocytoma to anaplastic glioblastoma) leads to modifications in both the survival and cell death pathways which overall confer a growth advantage to malignant cells and resistance to many cytotoxic stimuli. It has been demonstrated, however, that, in astrocytomas, several purinergic (in particular adenosinergic) pathways controlling cell survival and death are still effective and, in some cases, even enhanced, providing invaluable targets for purine-based chemotherapy, that still represents an appropriate pharmacological approach to brain tumors. In this chapter, the current knowledge on both receptor-mediated and receptor-independent adenosine pathways in astrocytomas will be reviewed, with a particular emphasis on the most promising targets which could be translated from in vitro studies to in vivo pharmacology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22879062     DOI: 10.1007/978-94-007-4719-7_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.

Authors:  Iolanda D'Alimonte; Eleonora Nargi; Mariachiara Zuccarini; Paola Lanuti; Patrizia Di Iorio; Patricia Giuliani; Lucia Ricci-Vitiani; Roberto Pallini; Francesco Caciagli; Renata Ciccarelli
Journal:  Purinergic Signal       Date:  2015-05-15       Impact factor: 3.765

2.  Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.

Authors:  Karen A Oliveira; Tharine A Dal-Cim; Flávia G Lopes; Cláudia B Nedel; Carla Inês Tasca
Journal:  Purinergic Signal       Date:  2017-05-23       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.